Landmark antibody study to test immune responses against COVID-19
17 April 2023
Thousands of immunosuppressed people, including patients at Oxford University Hospitals (OUH), have the chance to take part in a landmark new study investigating which people are still at the greatest risk of COVID-19 infection after vaccination.
Trial investigating potential treatment for fatigue relief in people with long COVID reports results
17 April 2023
Researchers from the University of Oxford have reported findings from a Phase 2 clinical trial investigating the efficacy of an investigational treatment against long COVID fatigue. The study (reported in Lancet eClinical Medicine) found participants given the treatment, developed by US pharmaceutical company Axcella Therapeutics, reported feeling less fatigued than those given a placebo.
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
14 April 2023
The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.
Study supports evidence ivermectin not effective to treat COVID-19
21 February 2023
High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.
Coronavirus Vaccines Research and Development Roadmap launched
21 February 2023
The Coronavirus Vaccines Research and Development Roadmap is a comprehensive plan to galvanize a global effort to protect the world from this large and dangerous family of viruses.
Communication at the crossroads of the immune system
6 February 2023
In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team in Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.
Major funding for Oxford will help find new cancer treatments
23 January 2023
Cancer Research UK and the National Institute for Health and Care Research are investing over £3 million across the next five years into The University of Oxford’s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.
New study reveals role of lymphatic system in bone healing
19 January 2023
It was previously assumed that bones lacked lymphatic vessels, but new research from the MRC Human Immunology Unit at Oxford's MRC Weatherall Institute for Molecular Medicine not only locates them within bone tissue, but demonstrates their role in bone and blood cell regeneration and reveals changes associated with aging.
Oxford vaccinologist Teresa Lambe honoured with Irish Abroad award
20 December 2022
A vaccine scientist from the University of Oxford recently received the prestigious Presidential Distinguished Service Award for the Irish Abroad for 2022, which recognises the contribution of members of the Irish diaspora.
Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment
16 December 2022
New research from the MRC Weatherall Institute of Molecular Medicine has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.
Alexandra Preston receives ASH Outstanding Abstract Achievement Award
12 December 2022
Alexandra Preston, a doctoral student from MRC Human Immunology Unit (MRC Weatherall Institute of Molecular Medicine), delivered a plenary talk on 11th December at the ASH Meeting and Exposition in New Orleans, Louisiana.
Research confirms important differences in colorectal cancer patients with a history of Inflammatory Bowel Disease
12 December 2022
IBD-associated colorectal cancers were found to occur in younger patients and have worse outcomes. Researchers call for urgent improvement of early detection methods to provide more risk-based and personalised care.
EAVI2020: The Quest for an HIV Vaccine
2 December 2022
In this long read published to coincide with International AIDS Day, we explore how an international collaboration – of which the University of Oxford is a key partner – has boosted HIV vaccine research. We thank our partners at Imperial College London for allowing us to reproduce and abridge this article.
Bacterial infections linked to one in eight global deaths, according to GRAM study
23 November 2022
Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings
First evidence drug resistant bacteria can travel from gut to lung, increasing infection risks
22 November 2022
A new Oxford University study released during World Antimicrobial Awareness Week has significant findings on how antimicrobial resistance (AMR) arises and persists. The results, published today in Nature Communications, provide the first direct evidence of AMR bacteria migrating from a patient’s gut microbiome to the lungs, increasing the risk of deadly infections.
University of Oxford study provides important insights into TB correlates of protection
7 November 2022
Researchers from the University of Oxford have today reported findings from a study that investigated whether previously identified correlates of protection associated with risk of full-blown tuberculosis (TB) disease could also be associated with risk of infection from the bacteria that causes TB - highlighting certain correlates in the process.
Therapeutic HIV vaccine with Oxford technology achieves encouraging results
4 November 2022
A phase I/IIa clinical trial that the University of Oxford collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was temporarily withdrawn.
Oxford retains top spot for medicine for twelfth consecutive year
27 October 2022
Oxford University has been ranked as the world's best institution for clinical and health teaching and research for the twelfth consecutive year in the latest Times Higher Education World University Rankings.
Leducq Foundation grant boosts cardiovascular research
11 October 2022
The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.
Night-time blood pressure assessment is found to be important in diagnosing hypertension
23 September 2022
Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.